[an error occurred while processing this directive] | [an error occurred while processing this directive]
Effects of niraparib on the radiosensitivity of human esophageal cancer cells and its mechanism
Zhao Fuzhen1, Feng Yue2, Ma Zhaoming1, Hu Lijun3, Sun Fei3, Wang Jianlin3, Yu Jingping2
1Department of Radiotherapy, the second People's Hospital of Lianyungang, Lianyungang 222000 China; 2Department of Radiotherapy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200021, China; 3Department of Radiotherapy, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou 213003, China
AbstractObjective To evaluate the effect of niraparib, the poly (ADP-ribose) polymerase (PARP) inhibitor, on the radiosensitivity of esophageal squamous cell carcinoma (ESCC) and to preliminarily investigate its mechanism. Methods Human esophageal squamous cell carcinoma cells ECA-109 and KYSE-150 were divided into the control, niraparib, single irradiation, combined (niraparib+irradiation) groups. Cell proliferation was measured by CCK-8 assay. The changes of cell survival rate were detected by colony formation assay. The changes of cell cycle and apoptosis were analyzed by flow cytometry. The number of γH2AX foci was detected by immunofluorescence, and the expression levels of PARP-1, cleaved-PARP, RAD51, mitogen-activated protein kinase (MAPK) [extracellular signal-regulated kinase 1 and 2 (ERK1/2) ] and p-MAPK (ERK1/2) proteins were determined by Western blot. All data were expressed as Mean±SD. Data between two groups conforming to normal distribution through the normality test were subject to independent sample t-test and multiple groups were analyzed using one-way ANOVA. Results In human ESCC cells ECA-109 and KYSE-150, the proliferation of ESCC cells was significantly inhibited by niraparib combined with irradiation, and the values of average lethal dose (D0), quasi-threshould dose(Dq), survival fraction after 2 Gy irradiation (SF2) in the combined group were decreased compared with those in the single irradiation group. The effect of irradiation alone on apoptosis of ECA-109 and KYSE-150 cells was limited. Compared to single irradiation group, irradiation combined with niraparib further increased the apoptosis rate in ESCC cells (P=0.015, P=0.006). In ECA-109 cells, G2/M phase arrest was significantly increased in combined group compared with irradiation alone group (P<0.001). In ECA-109 cells, the number of γH2AX foci in combined group was higher than that in the single irradiation group after 2 h, and showed a significantly slower decay of γH2AX foci (P<0.001). Moreover, niraparib combined with irradiation enhanced the radiation-induced cleavage of PARP-1 and down-regulated the expression of Rad51 and p-MAPK(ERK1/2). Conclusion Niraparib can increase the radiosensitivity of esophageal cancer cells by inhibiting cell proliferation, promoting cell apoptosis, inhibiting the repair of DNA damage and regulating the MARK-ERK signaling pathway.
Fund:The Second-level Talent Scientific Research Grant Project of "Project 333" of Jiangsu Province (BRA2019025); Changzhou Sci & Tech Program (CZ20210030); Major Science and Technology Project of Changzhou Health Commission (ZD202017)
Zhao Fuzhen,Feng Yue,Ma Zhaoming et al. Effects of niraparib on the radiosensitivity of human esophageal cancer cells and its mechanism[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 719-725.
Zhao Fuzhen,Feng Yue,Ma Zhaoming et al. Effects of niraparib on the radiosensitivity of human esophageal cancer cells and its mechanism[J]. Chinese Journal of Radiation Oncology, 2023, 32(8): 719-725.
[1] Fatehi Hassanabad A, Chehade R, Breadner D, et al.Esophageal carcinoma: towards targeted therapies[J]. Cell Oncol (Dordr), 2020,43(2):195-209. DOI: 10.1007/s13402-019-00488-2. [2] Wang LY, Liang C, Li FF, et al.PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs[J]. Int J Mol Sci, 2017,18(10):2111. DOI: 10.3390/ijms18102111. [3] Mateo J, Lord CJ, Serra V, et al.A decade of clinical development of PARP inhibitors in perspective[J]. Ann Oncol, 2019,30(9):1437-1447. DOI: 10.1093/annonc/mdz192. [4] Cohen DJ, Leichman L.Controversies in the treatment of local and locally advanced gastric and esophageal cancers[J]. J Clin Oncol, 2015,33(16):1754-1759. DOI: 10.1200/JCO.2014.59.7765. [5] Kumar S, Singh RK, Meena R.Emerging targets for radioprotection and radiosensitization in radiotherapy[J]. Tumour Biol, 2016,37(9):11589-11609. DOI: 10.1007/s13277-016-5117-8. [6] Murai J, Huang SY, Das BB, et al.Trapping of PARP1 and PARP2 by clinical PARP inhibitors[J]. Cancer Res, 2012,72(21):5588-5599. DOI: 10.1158/0008-5472.CAN-12-2753. [7] Moore K, Colombo N, Scambia G, et al.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2018,379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. [8] Wang H, Mu XY, He H, et al.Cancer radiosensitizers[J]. Trends Pharmacol Sci, 2018,39(1):24-48. DOI: 10.1016/j.tips.2017.11.003. [9] 李轩. 肿瘤放射敏感相关基因的研究进展[J].复旦学报(医学版),2014,41(4):560-564. DOI: 10.3969/j.issn.1672- 8467.2014.04.026. Li X.Research development of the correlative genes in cancer radiosensitization[J]. Fudan University Journal of Medical Sciences,2014,41(4):560-564. DOI: 10.3969/j.issn.1672-8467.2014.04.026. [10] Raavi V, Perumal V, F D Paul S. Potential application of γ- H2AX as a biodosimetry tool for radiation triage[J]. Mutat Res Rev Mutat Res, 2021,787:108350. DOI: 10.1016/j.mrrev.2020.108350. [11] Georgoulis A, Vorgias CE, Chrousos GP, et al.Genome Instability and γH2AX[J]. Int J Mol Sci, 2017,18(9) :1979. DOI: 10.3390/ijms18091979. [12] Luijsterburg MS, de Krijger I, Wiegant WW, et al. PARP1 links CHD2-mediated chromatin expansion and H3.3 deposition to DNA repair by non-homologous end-joining[J]. Mol Cell, 2016,61(4):547-562. DOI: 10.1016/j.molcel.2016.01.019. [13] Pascal JM.The comings and goings of PARP-1 in response to DNA damage[J]. DNA Repair (Amst), 2018,71:177-182. DOI: 10.1016/j.dnarep.2018.08.022. [14] Qvarnström OF, Simonsson M, Eriksson V, et al.gammaH2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids[J]. Int J Oncol, 2009,35(1):41-47. DOI: 10.3892/ijo_00000311. [15] Sun Y, McCorvie TJ, Yates LA, et al. Structural basis of homologous recombination[J]. Cell Mol Life Sci, 2020,77(1):3-18. DOI: 10.1007/s00018-019-03365-1. [16] Guo YJ, Pan WW, Liu SB, et al.ERK/MAPK signalling pathway and tumorigenesis[J]. Exp Ther Med, 2020,19(3):1997-2007. DOI: 10.3892/etm.2020.8454. [17] Zhu LG, Zhu C, Wang XX, et al.The combination of icotinib hydrochloride and fluzoparib enhances the radiosensitivity of biliary tract cancer cells[J]. Cancer Manag Res, 2020,12:11833-11844. DOI: 10.2147/CMAR.S265327. [18] Li S, Cui ZL, Meng XF. Knockdown of PARP-1 inhibits proliferation and ERK signals, increasing drug sensitivity in osteosarcoma U2OS cells[J]. Oncol Res, 2016,24(4):279-286. DOI: 10.3727/096504016X14666990347554. [19] Cohen-Armon M.PARP-1 activation in the ERK signaling pathway[J]. Trends Pharmacol Sci, 2007,28(11):556-560. DOI: 10.1016/j.tips.2007.08.005.
2023, Vol. 32 
